Alimta extends progression-free survival among patients in late-stage study
INDIANAPOLIS — Cancer patients taking a drug made by Eli Lilly extended the amount of time they survived without their disease worsening, according to results of a study announced Sunday.
Lilly said results of the phase-3 “PARAMOUNT” study of the injected drug Alimta (pemetrexed) extended progression-free survival in patients with nonsquamous nonsmall-cell lung cancer. The study focused on continuation maintenance when one of the same drugs used as a first-line treatment for cancer is continued as maintenance therapy in an effort to control the disease.
Results were presented Sunday at the 47th annual meeting of the American Society of Clinical Oncology in Chicago.
Study: Amylin’s metreleptin improves diabetes, lipid control among patients
SAN DIEGO — An investigational drug improved diabetes and lipid control in patients with partial lipodystrophy, according to a new study.
Amylin Pharmaceuticals announced Saturday results of a study of metreleptin, an analog of the human hormone leptin. Results of the study were presented at the 93rd annual meeting and expo of the Endocrine Society in Boston.
In the study, which the company is conducting under an investigational new drug treatment program authorized by the Food and Drug Administration, metreleptin is available to patients with rare forms of lipodystrophy who have one or more metabolic abnormalities, including diabetes and high levels of triglycerides in the bloodstream, also known as hypertriglyceridemia.
“We are committed to assisting patients who are living with lipodystrophy, a chronic and often debilitating disease that is not adequately managed by existing therapies,” Amylin SVP research and development Christian Weyer said. “Our expanded access program enables us to provide patients with metreleptin while we continue working with the FDA to make the medicine more broadly available to patients with this rare disorder.”
AstraZeneca honored by AmeriCares, HDMA
PHOENIX — AmeriCares and the Healthcare Distribution Management Association on Monday awarded the annual Power of Partnership Award to AstraZeneca for the company’s commitment to increasing access to health care for people in need, both here at home and throughout the developing world, during HDMA’s Business Leadership Conference on Monday.
In the past year, AstraZeneca renewed its support for the only breast cancer treatment program for Cambodia’s impoverished communities, assembled more than 14,000 hygiene kits for disaster survivors and, for the second year in a row, donated $5 million in medicines for chronically ill Americans.
“AstraZeneca supports our global health programs on every level, from product donations and cash grants to hands-on employee involvement after major disasters,” AmeriCares president and CEO Curt Welling said. “We’re restoring health and saving lives every day because of great corporate partners like AstraZeneca.”
The Power of Partnership Award was created by AmeriCares and HDMA to recognize medical manufacturing and distribution organizations that have shown exceptional dedication to expanding access to medicines and health care for disadvantaged populations.
“HDMA is proud to collaborate with AmeriCares to honor a partnership that has truly made a difference in the lives of patients worldwide,” HDMA president and CEO John Gray added. “We congratulate the AstraZeneca team, whose outstanding humanitarian efforts reflect HDMA members’ shared commitment to delivering lifesaving medicines, products and services to those in need.”